Noribogainalog

Noribogainalog (nor-IBG), also known as 9-hydroxyibogaminalog, is a drug of the ibogalog family related to noribogaine.^[1][2] It is a simplified analogue of noribogaine.^[1][2]

Noribogainalog

Clinical data
Other names	Nor-IBG; 9-Hydroxyibogaminalog
Identifiers
IUPAC name 3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indol-9-ol
CAS Number	411220-25-2
PubChem CID	154694300
ChemSpider	74888746
Chemical and physical data
Formula	C13H16N2O
Molar mass	216.284 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1CCC2=C(CC1)NC3=C2C=C(C=C3)O
InChI InChI=1S/C13H16N2O/c1-15-6-4-10-11-8-9(16)2-3-12(11)14-13(10)5-7-15/h2-3,8,14,16H,4-7H2,1H3 Key:OOROJSRWMMKEQK-UHFFFAOYSA-N

Pharmacology

The drug acts as a potent serotonin 5-HT_2A receptor partial agonist (EC₅₀Tooltip half-maximal effective concentration ≈ 90 nM; E_maxTooltip maximal efficacy = 35%).^[2] It also has activity as a dopamine transporter (DAT) chaperone.^[3] Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures.^[2] However, it does produce analgesic effects that can be diminished by the serotonin 5-HT_2A receptor antagonist ketanserin.^[2] The drug shows relatively low expected blood–brain barrier permeability.^[2]

History

Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021.^[1]

See also

• Ibogalog
• Noribogaine
• Catharanthalog
• Ibogainalog
• Ibogaminalog
• PNU-22394
• Tabernanthalog